{"slug":"radical","tag":"radical","variants":["radical"],"description":"No description yet","count":14,"kinds":{"technology":14},"related":[{"slug":"frontier","tag":"frontier","shared":14}],"records":[{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","status":"concept","tldr":"In vivo base and prime editing would rewrite a cancer's DNA letter by letter inside the body. It works in the liver for inherited disease; nobody has yet corrected a cancer this way in a person."},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","status":"concept","tldr":"Switching a gene off for good without changing the DNA sequence, by writing chemical marks onto it."},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","status":"preclinical","tldr":"Instead of attacking the cancer cell, engineering T cells to strip away the scaffolding and the suppressive immune cells that protect it."},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","status":"phase-2","tldr":"Bacteria that seek out the low-oxygen core of tumours, then manufacture a drug on the spot."},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","status":"preclinical","tldr":"Bacteriophage delivery uses viruses that infect bacteria, not human cells, as engineered shells whose coat proteins display tumour-homing peptides or antigens and carry drugs or vaccines. They are cheap and cannot replicate in people, but the work is preclinical: no oncology phage trial had reported efficacy by 2026, and the body clears them quickly."},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","status":"preclinical","tldr":"Some tumours contain bacteria and fungi that shelter cancer cells and break down chemotherapy. Killing them may make treatment work."},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","status":"preclinical","tldr":"Folded DNA machines that open only when they touch a tumour, releasing a payload or clotting the tumour's blood supply."},{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","status":"preclinical","tldr":"VHEE radiotherapy fires electrons at 100 to 250 MeV, energies that reach deep tumours and can be steered by magnets, aiming to deliver FLASH-speed radiation from a machine smaller and cheaper than a proton facility. It is still at the accelerator-development and preclinical stage: no patient had been treated by September 2026."},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","status":"preclinical","tldr":"Auger-electron therapy uses radioactive atoms such as iodine-125 or terbium-161 that release cascades of low-energy electrons travelling only nanometres to micrometres, so they kill a cell only if the atom sits on or inside its DNA and spare the neighbours. Terbium-161 can replace lutetium-177 in existing PSMA ligands; true nuclear delivery remains preclinical."},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","status":"preclinical","tldr":"Actinium-225 releases four alpha particles as it decays, but the daughters escape and irradiate the kidneys and salivary glands. Nanocarriers try to hold them in place."},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","status":"phase-2","tldr":"Tumours recruit nerves and use nerve signals to grow. Blocking that traffic, with beta-blockers or botulinum toxin, is being tested."},{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","status":"preclinical","tldr":"Chemotherapy leaves behind zombie cells that will not divide but poison their neighbours. Senolytics aim to clear them."},{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","status":"preclinical","tldr":"An ADC that carries a gene-silencing strand instead of a chemotherapy, so it can switch a protein off rather than poison the cell."},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","status":"phase-2","tldr":"Cancer interception vaccines immunise people who do not yet have cancer but carry a high inherited risk, such as Lynch syndrome carriers, against the antigens their future tumour is predicted to express, so memory T cells remove transformed cells early. Because healthy people accept risk for a probabilistic benefit, the safety bar is far higher and trials take years."}]}